Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the recipient of a significant drop in short interest in December. As of December 30th, there was short interest totalling 500 shares, a drop of 96.2% from the December 15th total of 13,200 shares. Based on an average daily volume of 30,800 shares, the days-to-cover ratio is currently 0.0 days.
Intellipharmaceutics International Stock Performance
Shares of OTCMKTS IPCIF remained flat at $0.08 during midday trading on Thursday. The firm has a market capitalization of $2.54 million, a P/E ratio of -0.32 and a beta of 1.51. Intellipharmaceutics International has a one year low of $0.06 and a one year high of $0.16. The company's 50-day moving average is $0.08 and its 200-day moving average is $0.09.
Get Intellipharmaceutics International alerts:About Intellipharmaceutics International
(Get Rating)
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.Featured Articles
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- Mid-Stream Operator Kinder Morgan: A High-Yield Value For 2023
- Why is T-mobile Down Despite Strong Preliminary Q4 Results?
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.